151 related articles for article (PubMed ID: 28025828)
1. Prognostic parameters and outcome after re-irradiation for progressive glioblastoma.
Zwirner K; Paulsen F; Schittenhelm J; Borchers C; Skardelly M; Zips D; Eckert F
Acta Neurol Scand; 2017 Sep; 136(3):239-245. PubMed ID: 28025828
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M
J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747
[TBL] [Abstract][Full Text] [Related]
3. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
4. Treatment of recurrent glioblastoma with stereotactic radiotherapy: long-term results of a mono-institutional trial.
Maranzano E; Anselmo P; Casale M; Trippa F; Carletti S; Principi M; Loreti F; Italiani M; Caserta C; Giorgi C
Tumori; 2011; 97(1):56-61. PubMed ID: 21528665
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years' experience of a single center.
Yilmaz MT; Kahvecioglu A; Yazici G; Mohammadipour S; Kertmen N; Cifci GC; Zorlu F
J Neurooncol; 2024 Apr; 167(2):295-303. PubMed ID: 38383875
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Scoccianti S; Krengli M; Marrazzo L; Magrini SM; Detti B; Fusco V; Pirtoli L; Doino D; Fiorentino A; Masini L; Greto D; Buglione M; Rubino G; Lonardi F; Migliaccio F; Marzano S; Santoni R; Ricardi U; Livi L
Radiol Med; 2018 Jan; 123(1):48-62. PubMed ID: 28879459
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
[TBL] [Abstract][Full Text] [Related]
8. Re-irradiation with radiosurgery for recurrent glioblastoma multiforme.
Torok JA; Wegner RE; Mintz AH; Heron DE; Burton SA
Technol Cancer Res Treat; 2011 Jun; 10(3):253-8. PubMed ID: 21517131
[TBL] [Abstract][Full Text] [Related]
9. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
[TBL] [Abstract][Full Text] [Related]
10. Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma.
Combs SE; Edler L; Rausch R; Welzel T; Wick W; Debus J
Acta Oncol; 2013 Jan; 52(1):147-52. PubMed ID: 22686472
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
Jablonska PA; Diez-Valle R; Pérez-Larraya JG; Moreno-Jiménez M; Idoate MÁ; Arbea L; Tejada S; Garcia de Eulate MR; Ramos L; Arbizu J; Domínguez P; Aristu JJ
PLoS One; 2019; 14(6):e0217881. PubMed ID: 31170245
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
[TBL] [Abstract][Full Text] [Related]
13. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
14. Elderly patients with glioblastoma multiforme treated with concurrent temozolomide and standard- versus abbreviated-course radiotherapy.
Chang-Halpenny CN; Yeh J; Lien WW
Perm J; 2015; 19(1):15-20. PubMed ID: 25663202
[TBL] [Abstract][Full Text] [Related]
15. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
16. Re-irradiation for recurrent glioblastoma multiforme: a critical comparison of different concepts.
Baehr A; Trog D; Oertel M; Welsch S; Kröger K; Grauer O; Haverkamp U; Eich HT
Strahlenther Onkol; 2020 May; 196(5):457-464. PubMed ID: 32016497
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival.
Lee J; Ahn SS; Chang JH; Suh CO
Yonsei Med J; 2018 Mar; 59(2):194-201. PubMed ID: 29436186
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated Stereotactic Re-irradiation and
Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results.
Pouessel D; Ken S; Gouaze-Andersson V; Piram L; Mervoyer A; Larrieu-Ciron D; Cabarrou B; Lusque A; Robert M; Frenel JS; Uro-Coste E; Olivier P; Mounier M; Sabatini U; Sanchez EH; Zouitine M; Berjaoui A; Cohen-Jonathan Moyal E
Oncologist; 2023 Sep; 28(9):825-e817. PubMed ID: 37196069
[TBL] [Abstract][Full Text] [Related]
19. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
Thon N; Eigenbrod S; Grasbon-Frodl EM; Lutz J; Kreth S; Popperl G; Belka C; Kretzschmar HA; Tonn JC; Kreth FW
J Neurol Neurosurg Psychiatry; 2011 Apr; 82(4):441-6. PubMed ID: 20861061
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic radiosurgery as an adjunct to surgery and external beam radiotherapy in the treatment of patients with malignant gliomas.
Gannett D; Stea B; Lulu B; Adair T; Verdi C; Hamilton A
Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):461-8. PubMed ID: 7673034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
